NCT00062894View on ClinicalTrials.gov

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2003

Study Completion Date

April 30, 2007

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Iodine I 131 Tositumomab

Trial Locations (6)

19104

Hospital of the University of Pennsylvania, Philadelphia

27710

Duke University Medical Center, Durham

33744

Bay Pines VA Medical Center, Bay Pines

60612

Rush Medical Center, Chicago

48109-0936

University of Michigan Medical Center, Ann Arbor

68198-7680

University of Nebraska Medical Center, Omaha

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00062894 - Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab | Biotech Hunter | Biotech Hunter